Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines reports developments for a central nervous system precision neuroscience biopharmaceutical company focused on therapies for disorders involving neuronal excitation-inhibition imbalance. Its recurring updates cover the Cerebrum small molecule platform, the Solidus antisense oligonucleotide platform, and product candidates across movement disorders and epilepsy, including ulixacaltamide, relutrigine, vormatrigine and elsunersen.
Company news commonly addresses FDA review activity, clinical trial data, scientific presentations, operating and financial results, commercial-readiness updates, equity inducement grants under Nasdaq rules and governance matters. Disease areas highlighted in its disclosures include essential tremor and developmental and epileptic encephalopathies associated with SCN2A and SCN8A.
Praxis Precision Medicines (NASDAQ: PRAX) will present a corporate overview at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Monday, June 8, 2026 at 8:00 a.m. ET. A live webcast and a replay (for ~180 days) will be available.
Praxis Precision Medicines (Nasdaq: PRAX) granted inducement restricted stock units on June 1, 2026, under its 2024 Inducement Plan. Awards cover an aggregate 2,754 shares of common stock for thirteen new non-executive employees and were approved under Nasdaq Listing Rule 5635(c)(4).
The RSUs vest in four equal annual installments, contingent on continued employment.
Praxis Precision Medicines (NASDAQ: PRAX) reported topline Phase 2/3 POWER1 results for vormatrigine in focal onset seizures. The primary endpoint, percent change in monthly seizure frequency, was not met. A key secondary endpoint, 50% responder rate, was achieved, with more pronounced seizure reduction at 30 mg in the study’s second half.
Vormatrigine was generally well-tolerated, with adverse event-related discontinuations under 10%, and about 90% of treated patients entered and remain in the open-label extension. Praxis is pausing enrollment in POWER2 while reassessing the vormatrigine program and continues preparing planned launches for relutrigine and ulixacaltamide.
Praxis Precision Medicines (NASDAQ: PRAX) reported Q1 2026 results and a corporate update. Key clinical and regulatory milestones include FDA acceptance of NDAs for ulixacaltamide in Essential Tremor (PDUFA Jan 29, 2027) and relutrigine in SCN2A/SCN8A DEEs (priority review, PDUFA Sep 27, 2026). EMBRAVE Part A showed a 77% placebo-adjusted reduction in monthly seizures for elsunersen. POWER1 topline for vormatrigine expected Q2 2026. Cash and investments were approximately $1.4 billion as of March 31, 2026, funding operations into 2028.
Praxis Precision Medicines (Nasdaq: PRAX) granted restricted stock units covering 5,420 shares on May 1, 2026 to 21 new non-executive employees under its 2024 Inducement Plan. Awards were made as inducements under Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest in four equal annual installments, subject to continued employment on each vesting date.
Praxis Precision Medicines (NASDAQ: PRAX) will report first quarter 2026 financial results and provide a corporate update before markets open on Thursday, May 7, 2026 at 8:30 am ET. The company will host a conference call and live webcast; registration and replay links are available on the investor website.
Praxis will also present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026 at 7:20 pm EDT, with a live webcast and a replay available for approximately 90 days.
Praxis Precision Medicines (NASDAQ: PRAX) said the FDA accepted its New Drug Application for ulixacaltamide HCl to treat essential tremor in adults and set a PDUFA target action date of January 29, 2027. No advisory committee meeting is expected.
The NDA is supported by positive Essential3 Phase 3 results and notes a consistent safety profile; ulixacaltamide received Breakthrough Therapy Designation in December 2025.
Praxis (NASDAQ: PRAX) will present expanded Phase 3 Essential3 data for ulixacaltamide at AAN 2026, including a plenary on maintenance of response and topline randomized withdrawal results. Ulixacaltamide has received FDA Breakthrough Therapy Designation; Praxis will present 15 scientific posters and oral sessions April 18–22, 2026.
Praxis Precision Medicines (NASDAQ: PRAX) reported positive topline EMBRAVE Part A results for elsunersen in pediatric SCN2A early-onset developmental and epileptic encephalopathy (DEE). Elsunersen showed a 77% placebo-adjusted seizure reduction from baseline (p=0.015) and sustained benefit in an open-label extension for up to one year.
Additional findings: 57% of patients had a ≥28-day seizure-free period; 100% of treated patients had improvements in sleep, motor function, muscle tone or attention; no drug-related serious adverse events were reported. Nine patients were randomized 3:1; dosing started at 1 mg with escalation to 8 mg.
Praxis Precision Medicines (Nasdaq: PRAX) announced on April 1, 2026 that its Compensation Committee granted restricted stock unit awards covering an aggregate of 3,558 shares to eighteen new non-executive employees under the 2024 Inducement Plan.
The awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4) and vest in four equal annual installments, subject to continued employment on each vesting date.